Veeva Systems Inc.: 10-K Risk Factor Changes

2026 vs 2025  ·  SEC EDGAR  ·  2026-05-22
Other years: 2025 vs 2024 · 2024 vs 2023
⚠ AI-Generated

The summary below was generated by an AI language model and may contain errors or omissions. All other content on this page is deterministically extracted from the original SEC EDGAR filing.

Veeva's 2026 risk factor disclosures show substantial continuity, with 33 of 45 total risks remaining unchanged, while 10 risks underwent substantive modifications addressing intellectual property protection, tax rate volatility, and competitive positioning. The company removed a data provider dependency risk - suggesting either reduced exposure or confidence in customer data access agreements - and added a new risk regarding share repurchase program effectiveness on shareholder returns. These shifts indicate evolving emphasis on capital allocation strategy and financial reporting complexity rather than fundamental business model threats.

✓ Deterministic extraction — no AI-generated data

Classification is based on semantic text similarity scoring and may include approximations. “No match” means no high-confidence textual match was found — not necessarily that a section was removed.

1
New Risks
1
Removed
10
Modified
33
Unchanged
🟢 New in Current Filing

Our share repurchase program may not enhance long-term shareholder value.

In January 2026, our board of directors authorized a share repurchase program of up to $2 billion of our outstanding shares of common stock. Under the program, we may repurchase shares of common stock from time to time through open market purchases, in privately negotiated…

Read full text

In January 2026, our board of directors authorized a share repurchase program of up to $2 billion of our outstanding shares of common stock. Under the program, we may repurchase shares of common stock from time to time through open market purchases, in privately negotiated transactions, or by other means, including through the use of trading plans intended to qualify under Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), in accordance with applicable securities laws and other restrictions, including Rule 10b-18 under the Exchange Act. The timing and total amount of any share repurchases will depend upon business, economic and market conditions, corporate and regulatory requirements, prevailing stock prices, and other considerations. The share repurchase program has a term of two years, may be suspended or discontinued at any time, and does not obligate us to acquire any amount of common stock. Any repurchased shares of common stock will be retired. Any failure to repurchase stock after we have announced our intention to do so may negatively impact our reputation and investor confidence in us and may negatively impact our stock price. The existence of our share repurchase program could cause our stock price to trade higher than it otherwise would and could potentially reduce the market liquidity for our stock. Our share repurchase program may not enhance long-term stockholder value because the market price of our common stock may decline below the levels at which we repurchased shares, and short-term stock price fluctuations could reduce the effectiveness of this program. Repurchasing our common stock will reduce the amount of cash we have available to fund working capital, capital expenditures, strategic acquisitions or business opportunities, and other general corporate purposes, and we may fail to realize long-term stockholder value from our share repurchase program. Furthermore, the timing and amount of repurchases, if any, will be subject to liquidity, market and economic conditions, any excise tax on share repurchases, compliance with applicable legal requirements such as Delaware surplus and solvency tests, and other relevant factors.

🔴 No Match in Current Filing If the third-party providers of healthcare professional and healthcare organization data and prescription drug sales data do not allow our customers to upload and use such data in our solutions, the demand for our solutions may decrease, and our business may be negatively impacted. 🔒
🟡 Modified Any failure to protect our intellectual property rights could impair our ability to protect our proprietary technology and our brand. 🔒
🟡 Modified Unanticipated changes in our effective tax rate and additional tax liabilities, including as a result of our international operations or implementation of new tax rules, could harm our future results. 🔒
🟡 Modified We face intense competition in markets in which we operate and if we do not compete effectively, we may lose customers and our business and operating results could be adversely affected. 🔒
🟡 Modified Summary of Risk Factors 🔒
🟡 Modified The migration of our CRM customers to our Vault CRM applications built on our own Veeva Vault platform could cause business disruptions for customers and adversely affect our operating results. 🔒
🟡 Modified Our historic growth rates of total revenues and subscription revenues should not be viewed as indicative of our future performance. 🔒
🟡 Modified Increasingly complex regulations relating to privacy, data protection, and cybersecurity are burdensome, may reduce demand for our solutions, and non-compliance may impose significant liabilities. 🔒
🟡 Modified Incorporating AI in our solutions or other uses of AI may result in reputational harm and increased liability. 🔒
🟡 Modified We may not be able to sustain the level of profitability we have achieved in the past. 🔒
🟡 Modified We are currently dependent upon Salesforce’s platform for our Veeva CRM application. 🔒
11 more changes in this filing

Full diff access, historical comparisons, and cross-company signal tracking.

Get full access — from $29/month Already a Pro subscriber? View full diff →